| Completed | 4 | 157 | Europe | Benralizumab | NHS Greater Glasgow and Clyde, University of Glasgow, AstraZeneca, Queen's University, Belfast, Bosch Healthcare Solutions GmbH, InHealthcare, University of Leicester, University of Plymouth, Vitalograph | Asthma | 02/24 | 04/24 | | |
TRECOS, NCT06264674: Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (). |
|
|
| Active, not recruiting | 3 | 837 | Europe, RoW | CHF5993 200/6/12.5 μg pMDI HFA-152a, HFA-152a propellant, Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a, HFA-134a propellant | Chiesi Farmaceutici S.p.A. | Asthma | 07/25 | 09/25 | | |
| Recruiting | N/A | 120 | Europe | no study intervention. Patients receive standard clinical care, no intervention. observational study | University Hospital Southampton NHS Foundation Trust, Portsmouth Hospitals NHS Trust, University of Derby | Severe Eosinophilic Asthma, Psychological Distress, Anxiety, Depression, Psychological Stress, Psychological Adjustment, Psychological Disorder, Psychosocial Problem, Psychosocial Stressor, Psychological, Emotions, Emotional Disorder, Emotional Dysfunction, Emotional Distress, Adjustment, Adjustment, Emotional, Coping Behavior | 12/24 | 12/24 | | |
